Development asset linked to Immix Biopharma in public FDA and regional records.
biotech · Advanced Solid Tumor · Solid Tumor, Adult · IMMX
Immix Biopharma
Immix Biopharma drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Los Angeles, USA HQ
2012 Founded
39 Employees
Public company Type
IMMX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Los Angeles, USA
- Founded
- 2012
- Employees
- 39
- Programs
- 3
- Drugs
- 2
- Patents
- 2
Immix Biopharma pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Immix Biopharma drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
tislelizumab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Immix Biopharma's portfolio. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor